Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.
- DOI
- 10.1016/s2213-8587(26)00138-5
- Published
- 2026 Oct
- Container
- The lancet. Diabetes & endocrinology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-26-00138-5,
title = {Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.},
author = {Yabe D and Shiraiwa T and Ugai H and Takeuchi M and Suzuki R},
year = {2026},
journal = {The lancet. Diabetes \& endocrinology},
doi = {10.1016/s2213-8587(26)00138-5},
url = {https://doi.org/10.1016/s2213-8587(26)00138-5}
}RIS
TY - JOUR TI - Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial. AU - Yabe D AU - Shiraiwa T AU - Ugai H AU - Takeuchi M AU - Suzuki R PY - 2026 JO - The lancet. Diabetes & endocrinology DO - 10.1016/s2213-8587(26)00138-5 UR - https://doi.org/10.1016/s2213-8587(26)00138-5 ER -
APA
D, Y., T, S., H, U., M, T., & R, S. (2026). Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(26)00138-5
Source records
- pubmed · retrieved 2026-09-26T02:30:52.356Z